Rimegepant: New Hope for Migraine Sufferers Unresponsive to Traditional Treatments

Research Summary

A new study published in Cephalalgia has evaluated the effectiveness and safety of rimegepant, a 75 mg orally disintegrating tablet, for preventing episodic migraines in adults who did not respond well to traditional oral preventive medications. Conducted over a 12-week period, this phase 4 trial included 652 participants who experienced 4-14 migraine days per month. Participants who took rimegepant every other day showed a significant reduction in monthly migraine days compared to those on a placebo, with an average decrease of 2.1 days versus 0.5 days. Additionally, rimegepant improved quality of life and was well tolerated, with a similar safety profile to the placebo. The study highlights rimegepant's potential as a preventive treatment for those with limited responses to existing migraine medications.

Study Details

📄 Title: A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.

👥 Research Team: Pozo-Rosich P et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.